

## Prevalence of quinolone resistance genes mediated by plasmids in ciprofloxacin-resistant strains *Escherichia coli* isolates in a sample of patients with urinary tract infections

Murtadha M Hussein A Kadhimi<sup>1,\*</sup>, Salih Abdul Mahdi<sup>1</sup>, Mohammed A. Aboktifa<sup>2</sup>

<sup>1</sup>Department of Medical Biotechnology, College of Biotechnology, Al-Qasim Green University, Babylon -Iraq.

<sup>2</sup>Department of Physiology, college of veterinary, Al-Qasim Green University, Babylon - Iraq.

\*Corresponding Author: Mobile no: + 9647832678804, Email: [drsalih@biotech.uoqasim.edu.iq](mailto:drsalih@biotech.uoqasim.edu.iq)

### Abstract

Genetic variations in the unique bacterial genomic region may lead to resistance of quinolone (bactericidal antibiotic) compounds or via by transmission with plasmids and then possession of plasmid-mediated quinolone resistance (PMQR) determinants, involved, *qnrA*, *qnrB*, and *qnrS*. Current study aimed to detect the most frequency of PMQR genes that may lead to increasing *Escherichia coli* (*E. coli*) resistance to ciprofloxacin antibiotic. 100 of *E. coli* isolates were collected and identified. Molecular detection achieved by 16S rDNA marker. All of *E. coli* isolates were subjected to PCR testing to determine the frequency of the PMQR genes (*qnrA*, *qnrB*, and *qnrS*). Concerning antibiotic resistance results revealed that 62% (n=62) isolate were non-susceptible and/or resistance of ciprofloxacin antibiotic. It was found that 58% of all *E. coli* isolates had one or more of PMQR genes, Also 41% (n = 41/58) were harbored single form of PMQR genes. Additionally, it was discovered that 29% (n = 12), 32% (n = 13), and 39% (n = 16) of the isolates had the *qnrA*, *qnrB*, and *qnrS* genes respectively. Conclusion; 58% of all isolates had one or more of PMQR genes and the *qnrS* genes were the most recurrence among PMQR genes.

**Key words:** PMQR, *E. coli*, gene, quinolone, resistance.

### 1. Introduction

One of most quinolone compounds that reported effective systemic activity was ciprofloxacin antibiotic<sup>1,2,3</sup>. Being utilized in clinical settings to treat a variety of urinary tract infections, including those brought on by *E. coli*<sup>4,5</sup>. *E. coli* infections of the urinary tract are rather common. Fluoroquinolones were a lot used for UTIs treatment and improper use of these antibiotics has led to antibiotic resistance. Ciprofloxacin is most commonly fluoroquinolone antibiotic used for the treatment of UTIs<sup>5,6</sup>. Previously recorded scientific facts demonstrated that quinolone resistance genes that plasmid-related a large number of them included *qnr* gene alleles have been found carried on plasmid or bacterial chromosome<sup>7,8</sup>.

a large number of *qnr* alleles have been found on plasmids or bacterial chromosome. Reported that about one hundred *qnr* genes have been detected and described from Enterobacteriaceae and classified into five distinct families (*qnrA*, *qnrB*, and *qnrS*). The selection of mutant strain and/or gene approved or facilitated by the mechanism of plasmid-mediated quinolone resistance<sup>9,10</sup>.

### 2. Material and methods

One hundred (100) isolates of *Escherichia coli* urine were taken from people who had urinary tract infections. Detection of Isolates was achieved through biochemical test, and confirmed VITEK-2 compact system. Molecular detection depending on 16S rDNA as a molecular marker. By using the PCR method, the PMQR genes *qnrA*, *qnrB*, and *qnrS* were examined in all *E. coli* isolates. By using the disk diffusion technique and regular diagnostics, the susceptibility to the antibiotic ciprofloxacin was found. Used concentration of ciprofloxacin antibiotic was (5µl) performed according to Clinical Standards Institute Guideline<sup>11</sup>. PMQR gene detection achieved through DNA isolation of *E. coli* isolates. Using a kit supplemented by Geneaid (UK), the isolation of bacterial genomic DNA


was carried out. For all PCR isolated DNA was used as templates<sup>12,13</sup>. (Bioneer, Korea) produced the forward and reverse primers<sup>7,8</sup> (Table 1), which were kept at -20°C. The manufacturing company (Bioneer- Korea), claims that PCR was successful in a 25µl total volume. Successful PCR amplifications were confirmed by agarose gel electrophoresis.

**Table 1.** Show sequences of primers that were used in present study.

Primers	Sequence of Primers	Size product (bp)	Ref.
16SrDNA	F: AGAGTTTGATYMTGGCTCAG R: CTACGGCTACCTTGTTACG	1500	(7)
<i>qnrA</i>	F: ATTTCTCACGCCAGG ATTTG R: GATCGGCAAAGGTTA GGTCA	516 (bp)	(8)
<i>qnrB</i>	F: GATCGTGAAAGCCAG AAAGG R: ACGATGCCTGGTAGTTGTCC-3	469 (bp)	
<i>qnrS</i>	F: ACGACATTCGTCAACTGCAA R: TAAATTGGCACCCCTGTAGGC	417 (bp)	

## Results

In current study all of 100 isolated clinical samples are detected as *Escherichia Coli*. After being amplified by a polymerase chain reaction, the *E. coli* ITS1 regions, which are internally transcribed 16S rDNA spacers, were examined. PCR products (figure 1) were sent to gradient analysis to identify the bacterial isolates. Molecular analysis results revealed that all of hundred isolates of *E. coli* were positive and/or harbored for 16S rDNA genes.



**Figure 1:** Show PCR product (1500 bp) of *E coli* with 2% agarose. Lane 1-16: PCR products for 16S rDNA genes, Lane L : DNA marker (1500bp).

### **E.coli Resistance to Ciprofloxacin Antibiotic and its Relation with *qnr* genes:**

Current study demonstrated that 58% (n =58) out of 100 isolates harbored one or more of PMQR genes divided to seventeen (17) isolates harbored more than one of PMQR genes and forty one (41) isolates distributed as 29% (n =12), 32% (n =13), and 39% (n =16) were harboring single form of *qnrA*, *qnrB*, and *qnrS* respectively (Figure 2,3,4 respectively). On the other hand 62% (n =61) out of 100 isolates were nonsusceptible of ciprofloxacin antibiotic. All of 58 isolates that had PMQR genes showed ciprofloxacin resistance arranged from high 57% (n=34/58) to low 43% (n= 24/58). There was no significant difference between the intensity of resistance and the type of PMQR (*qnrA*, *qnrB*, *qnrS*) genes.




Figure 2. : Show gel electrophoresis of PCR products (1500 bp) L: 1500 bp DNA marker; *qnrA* lane: (3,4,5,7,8,10,11,16,18,19,22,28). PCR size product 516 bp.




Figure 3: Show gel electrophoresis of PCR products (1500 bp) L: 15000 bp DNA marker; *qnrB* gene lane: (3,5,6,7,8,14,15,19,20,22,24,28,30). PCR size product was 469 bp.




Figure 4. : Show gel electrophoresis of PCR products (1500 bp) L1: 15000 bp DNA marker, *QnrS* gene lane: (3,5,6,7,10,11,12,15,19,20,22,24,25,26,28,30). PCR size product was 417 bp.

## Discussion

*Escherichia coli* is the most common cause of urinary tract infections, which are the most common bacterial infection<sup>14</sup>. On the other hand quinolones compounds are most frequently employed antibacterial agents for treating a variety of infections. caused by *Escherichia Coli*. Previous studies reported that plasmid-mediated quinolones resistance is being increasingly especially in Asia<sup>15</sup>. However reports about the prevalence of PMQR genes among Iraqi enterobacterial isolates were limited. So the present study contributed to highlight on the spread of PMQR genes frequency among clinical samples of *E.Coli* collected from urine samples of Iraqi urinary tract infection patients..

Present results in current study are consistent with previous studies and do not agree with others. Hog bin kim et al. reported in 2009 that only 10% of *E. Coli* isolates contained one or more *qnr* genes<sup>16</sup>. Another reports in 2016 among Iranian population showed that *qnrA* and *qnrB* were not found and out of 136 *E.Coli* isolates just 2.9% were carried *qnrS* gene only<sup>17</sup>. Our findings don't agree with both above studies but it is in line with other study<sup>18</sup> conducted in 2014, which showed that 72.8% (59/81 isolates) of *E.Coli* among Korean population had one or more of PMQR genes.

According to assumptive scientific truths that *qnr* genes encode several proteins that protect DNA gyrase from inhibition by quinolones compounds like ciprofloxacin antibiotics<sup>19,20</sup> and the final result is increasing of bacterial resistance. But the important scientific fact that has been observed through this study and other studies is the significant vary in the prevalence of *qnr* genes from one place to other among worldwide<sup>21,22</sup>. Concerning resistance of ciprofloxacin antibiotic our findings reported that 62% of all *E.Coli* isolates were nonsusceptible of ciprofloxacin antibiotic and these data were in agreement with the results recorded by Naji et al 2017 they have been reported, resistance range arranged from (50 to 70 %) with ciprofloxacin antibiotic<sup>9</sup>. The results of the current investigation were also found to be higher than or in conflict with those discovered in Nigeria by Ekwealor et al. in 2016, who reported<sup>10</sup> that the rate of ciprofloxacin resistance was (27%).

Through the current and previous studies, concluded that there is a fact that the *qnr* genes increase the rates of *E. Coli* bacteria resistance, but with great variation from one race to another and from one region to another. Concerning of resistance range in present study, 58% of hundred isolates were *E.coli* it ranged from high to low resistance that correspond with other studies achieved by Hamza et al 2019 and Saenz et al 2015 they have been recorded average resistances of *E.coli* are 36% and 38% respectively of *E.Coli* isolated from urine samples<sup>12,13</sup>. Because that *E.coli* are widely prevalence in patients who have undergone instrumentation or catheterization of UTIS and resulted in eighty percent (80%) of cases had *Escherichia. coli* among Gram-negative bacteria as a reason of catheter-associated urinary tract infections<sup>23</sup>.

The scientific and logical interpretation for such changes in the rates and/or percentage of *E.Coli* resistance to antibiotics and the rates of recurrence of PMQR genes, it is not easy to suggest a single cause or factor, but it may be linked to multiple environmental and bacterial factors that played an important role in creating such variations. On the other hand the time may be one of factors that contributed in such variations to occur. Since it was discovered in 1998 that ciprofloxacin antibiotic resistance grew over time ( $P = 0.001$ ) and the prevalence of PMQR genes has grown, generally increased ( $P=0.20$ )<sup>24</sup>. Other suggestion to understanding like such variation also may be because the selection area of *E. coli* isolates and the changing in circumstances conditions and may be the diversity of geographical areas. However, other elements such as increased intracellular concentration, overexpression of the efflux pump, and mutations (DNA gyrase enzymes) may also be equally efficient in this regard. So the prevalence of PMQR genes and their effecting on bacterial resistance remains great challenge and more studied are needed.

## Conclusion

Present study concluded that 58% of *E.Coli* included one or more of PMQR genes and it was found that *qnrS* gene is the more recurrence among PMQR genes in present study.

## Reference:

1. Huang SY, Zhu XQ, Wang Y, Liu HB, Dai L, He JK.. Co-carriage of *qnrS1*, *floR*, and *blaCTX-M-14* on a multidrug-resistant plasmid in *Escherichia coli* Isolated from Pigs. Foodborne Pathog. Dis. 2012; 9:896–901 .

2. AL-saadi SA. Molecular Characterization of Some Virulence Factors of Clinical Isolates of *Escherichia coli*. Iraq. Babylon University. PHD thesis. College of Medicine 2018.
3. Al-Mayahie SM. Phenotypic and genotypic comparison of ESBL production by vaginal *Escherichia coli* isolates from pregnant and non-pregnant women. *Annals of Clinical Microbiology and Antimicrobials* 2013;12: 12-7.
4. Yousefi S, Mojtahedi A, Shenagari M, Atrkar-roushan Z. The relation of qnr genes to the induction of resistance to ciprofloxacin in *Escherichia coli*. *SJKU* 2015; 5:52-60.
5. Lodish, H, Berk, A, Matsudaira, P, Kaiser CK, Krieger, M, Scott MP, Zipursky SL. and Darnell, J. *Molecular Cell Biology* 2004., W. H. Freeman, New York.
6. Varughese L.R., Rajpoot M., Goyal S., Mehra R., Chhokar V. and Beniwal V. Analytical profiling of mutations in quinolone resistance determining region of gyrA gene among UPEC. *PLoS ONE* 2018; 13:1-9.
7. Shams E, Firoozeh F, Moniri R. and Zibaei M. (2015). Prevalence of Plasmid-Mediated Quinolone Resistance Genes among Extended-Spectrum  $\beta$ -Lactamase-Producing *Klebsiella pneumoniae* Human Isolates. *Iran Journal of Pathogens* 2015; Article ID 434391, 7 pages.
8. AL-saadi, S.A.. Molecular Characterization of Some Virulence Factors of Clinical Isolates of *Escherichia coli*. Iraq babylon university. PHD thesis. College of Medicine 2018.
9. Naji EN, Ali MR, Pirko EY.. The Relationship between Phylogenetic Typing and Antimicrobial Susceptibility Patterns for *Escherichia coli* Isolated from UTIs at Many Hospitals in Baghdad City. *Iraqi National Journal of Nursing Specialties* 2017;30:1-12
10. Ekwealor, P. A., Ugwu, C., Ezeobi, I., Amalukwe, G., Ugwu B.C. and Okezie, U.(2016). Antimicrobial Evaluation of Bacterial Isolates from Urine Specimen of Patients with Complaints of Urinary Tract Infections in Awka, Nigeria. *Hindawi Publishing Corporation International Journal of Microbiology* 2017; Article ID 9740273, 6 pages.
11. Wayne, PA: clinical laboratory standards 2013. Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing.23th informational supplement (M100-S23).
12. Hamza H.J. Plasmid-Mediated Quinolone Resistance Genes and Phylogenetic groups Detection in Uropathogenic *Escherichia coli* Isolated from Babylon Hospitals. Iraq. Babylon University.PHD thesis. College of Medicine 2019; 60-3.
13. Saenz M, Hajer K, Mohamed S. and Sana F.(2015). Occurrence of virulence genes in ESBL-producing *Escherichia coli* isolates from urine. *Cell Infect Microbiol* 2015; 5: 322-344.
14. Jacobsen SM, Stickler DJ, Mobley HL. Complicated catheter-associated urinary tract infections due to *Escherichia coli* and *Proteus mirabilis*. *Clin Microbiol Rev* 2008;21: 26-59.
15. Dalhoff A. Global fluoroquinolone resistance epidemiology and implications for clinical use. *Interdiscip Perspect Infect Dis* 2012; Article ID 976273, 37 pages
16. Hong Bin Kim, Chi Hye Park, Chung Jong Kim, Eui - Chong Kim, George A. Jacoby, and David C. Hooper. Prevalence of Plasmid Mediated Quinolone Resistance Determinants over a 9-Year Period. *Antimicrobial Agents and Chemotherapy* 2009; 53: 639–645.
17. Maryam Rezazadeh, Hamid Baghchesaraei, Amir Peymani. Plasmid –mediated quinolones-resistance (qnr) Genes in clinical isolates of *Escherichia Coli* collected from several Hospitals of Qazvin and Zanjan provinces. *Osong Public Health Res Perspect* 2016; 7:307-312.
18. Hee Young Yang MD1, You Sun Nam MSc2, Hee Joo Lee MD3. prevalence of plasmid-mediated quinolone resistance genes among ciprofloxacin-nonsusceptible *Escherichia coli* and *Klebsiella pneumoniae* isolated from blood cultures in Korea. *Can J Infect Dis Med Microbiol*. 2014;25:163–169.
19. Tran JH, Jacoby GA, Hooper DC. Interaction of the plasmidencoded quinolone resistance protein Qnr with *Escherichia coli* DNA gyrase. *Anti-microb Agents Chemother* 2005;49:118-25.

20. Tran JH, Jacoby GA, Hooper DC. Interaction of the plasmid encoded quinolone resistance protein QnrA with *E. scherichiacoli* topoisomerase IV. *Antimicrob Agents Chemother* 2005;49:3050-2.
21. Wang A, Yang Y, Lu Q, et al. Presence of qnr gene in *Escherichia coli* and *Klebsiella pneumoniae* resistant to ciprofloxacin isolated from pediatric patients in China. *BMC Infect Dis* 2008;8:68-77.
22. Kim ES, Jeong JY, Jun JB, et al Prevalence of aac (6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. *Antimicrob Agents Chemother* 2009;53:2643-5.
23. FarajzadehSheikh A, Veisi H, Shahin, M, Getso M., & Farahani A. Frequency of quinolone resistance genes among extended-spectrum  $\beta$ -lactamase (ESBL)-producing *Escherichia coli* strains isolated from urinary tract infections. *Tropical medicine and health* 2019;47:19-32
24. Martínez-Martínez, L, A. Pascual, and GA. Jacoby. 1998. Quinolone resistance from a transferable plasmid. *Lancet* 1998; 351:797–799.